Sales in the immuno-oncology market surpassed KRW 700 billion last year, driven by the surge in sales of Keytruda and Opdivo. The market has more than tripled in size over the past 4 years. Keytruda and Opdivo together accounted for 72.4% of the market and generated more than KRW 500 billion in sales. The market’s prospects are also bright with major immuno-oncology drugs showing additional efficacy in various solid tumors.

According to the market research institution IQVIA on the 27th, the total immuno-oncology treatment market has recorded KRW 730.8 billion in the past year, a 46.6% increase from the KRW 498.3 billion in the previous year.

Sales have been growing steeply in the immuno-onc